Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
Zendal Group
Welcome,
Profile
Billing
Logout
Products
Diseases
Products
Trials
News
|||||
|||||
IMUNO BGC Moreau RJ
/
Zendal Group
New P2 trial:
Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis
(clinicaltrials.gov) - Jun 12, 2019
P2
, N=306, Recruiting,
Sponsor: Biofabri, S.L